Treatment of Sarcopenia and Cachexia in the Elderly

  • Charles P. Lambert
  • William J. Evans
  • Dennis H. Sullivan


Cachexia is defined as physical wasting with loss of muscle mass and weight that is caused by disease [1]. It is common for elderly individuals who have disease to exhibit cachexia.Additionally,muscle mass loss is characteristic of the conditions of frailty and sarcopenia. Sarcopenia is the age-related loss of muscle mass [2]. Physical frailty has been characterised by Fried et al. [3] as a condition that results from reduced strength, reduced gait velocity, reduced physical activity, weight loss, and exhaustion. Clearly, sarcopenia and frailty could be classified as cachectic conditions because they are associated with muscle mass loss. This chapter will describe the causes of sarcopenia, treatment of sarcopenia, causes of cachexia in elderly individuals, and treatment of cachexia in elderly individuals.


Chronic Obstructive Pulmonary Disease Muscle Mass Resistance Training Chronic Obstructive Pulmonary Disease Patient Anabolic Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
  2. 2.
    Rosenberg IH (1989) Summary comments. Am J Clin Nutr 50:1231–1233Google Scholar
  3. 3.
    Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156PubMedGoogle Scholar
  4. 4.
    Morales A, Heaton JP, Carson CC3rd (2000) Andropause: a misnomer for a true clinical entity. J Urol 163:705–712PubMedCrossRefGoogle Scholar
  5. 5.
    Volpi E, Sheffield-Moore M, Rasmussen BB, Wolfe RR (2001) Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. JAMA 286:1206–1212PubMedCrossRefGoogle Scholar
  6. 6.
    Welle S, Thornton C, Jozefowicz R, Statt M (1993) Myofibrillar protein synthesis in young and old men. Am J Physiol 264:E693–E698PubMedGoogle Scholar
  7. 7.
    Welle S, Thornton C, Statt M (1995) Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. Am J Physiol 268:E422–E427PubMedGoogle Scholar
  8. 8.
    Balagopal P, Rooyackers OE, Adey DB et al (1997) Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol 273:E790–E800PubMedGoogle Scholar
  9. 9.
    Hasten DL, Pak-Loduca J, Obert KA, Yarasheski KE (2000) Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23–32 yr olds. Am J Physiol Endocrinol Metab 278:E620–E626PubMedGoogle Scholar
  10. 10.
    Yarasheski KE, Zachwieja JJ, Bier DM (1993) Acute effects of resistance exercise on muscle protein synthesis rate in young and elderly men and women. Am J Physiol 265:E210–E214PubMedGoogle Scholar
  11. 11.
    Trappe T, Williams R, Carrithers J et al (2004) Influence of age and resistance exercise on human skeletal muscle proteolysis: a microdialysis approach. J Physiol 554:803–813PubMedCrossRefGoogle Scholar
  12. 12.
    Doherty TJ, Vandervoort AA, Taylor AW, Brown WF (1993) Effects of motor unit losses on strength in older men and women. J Appl Physiol 74:868–874PubMedCrossRefGoogle Scholar
  13. 13.
    Goldspink DF (1976) The effects of denervation on protein turnover of rat skeletal muscle. Biochem J 156:71–80PubMedGoogle Scholar
  14. 14.
    Medina R, Wing SS, Goldberg AL (1995) Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 307:631–637PubMedGoogle Scholar
  15. 15.
    Mauras N, Hayes V, Welch S et al (1998) Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 83:1886–1892PubMedCrossRefGoogle Scholar
  16. 16.
    Melton LJ,3rd, Khosla S, Riggs BL (2000) Epidemiology of sarcopenia. Mayo Clin Proc 75:S10–S12; discussion S12–S13PubMedGoogle Scholar
  17. 17.
    Perry HM3rd, Miller DK, Patrick P, Morley JE (2000) Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 49:1085–1091PubMedCrossRefGoogle Scholar
  18. 18.
    Baumgartner RN, Waters DL, Gallagher D et al (1999) Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107:123–136PubMedCrossRefGoogle Scholar
  19. 19.
    Iannuzzi-Sucich M, Prestwood KM, Kenny AM (2002) Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 57:M772–M777PubMedGoogle Scholar
  20. 20.
    Iranmanesh A, Lizarralde G, Veldhuis JD (1991) Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73:1081–1088PubMedCrossRefGoogle Scholar
  21. 21.
    Veldhuis JD, Liem AY, South S et al (1995) Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 80:3209–3222PubMedCrossRefGoogle Scholar
  22. 22.
    Veldhuis JD, Iranmanesh A, Weltman A (1997) Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine 7:41–48PubMedGoogle Scholar
  23. 23.
    Corpas E, Harman SM, Blackman MR (1993) Human growth hormone and human aging. Endocr Rev 14:20–39PubMedCrossRefGoogle Scholar
  24. 24.
    Roubenoff R, Harris TB, Abad LW et al (1998) Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 53:M20–M26PubMedGoogle Scholar
  25. 25.
    Visser M, Pahor M, Taaffe DR et al (2002) Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 57:M326–M332PubMedGoogle Scholar
  26. 26.
    Greiwe JS, Cheng B, Rubin DC et al (2001) Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 15:475–482PubMedCrossRefGoogle Scholar
  27. 27.
    Barbieri M, Ferrucci L, Ragno E et al (2003) Chronic inflammation and the effect of IGF-1 on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 284:E481–E487PubMedGoogle Scholar
  28. 28.
    Payette H, Roubenoff R, Jacques PF et al (2003) Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J Am Geriatr Soc 51:1237–1243PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell WW, Trappe TA, Wolfe RR, Evans WJ (2001) The recommended dietary allowance for protein may not be adequate for older people to maintain skeletal muscle. J Gerontol A Biol Sci Med Sci 56:M373–M380PubMedGoogle Scholar
  30. 30.
    Brodsky IG, Suzara D, Hornberger TA et al (2004) Isoenergetic dietary protein restriction decreases myosin heavy chain IIx fraction and myosin heavy chain production in humans. J Nutr 134:328–334PubMedGoogle Scholar
  31. 31.
    Roubenoff R, Hughes VA (2000) Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 55:M716–M724PubMedGoogle Scholar
  32. 32.
    Weimer J (1998) Factors Affecting Nutrient Intake of the Elderly. Washington, D.C., US Department of Agriculture, Economic Research Service, Economic Research ServiceGoogle Scholar
  33. 33.
    Hughes VA, Frontera WR, Roubenoff R et al (2002) Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am J Clin Nutr 76:473–481PubMedGoogle Scholar
  34. 34.
    Leeuwenburgh C (2003) Role of apoptosis in sarcopenia. J Gerontol A Biol Sci Med Sci 58:999–1001PubMedGoogle Scholar
  35. 35.
    Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C (2002) The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci 959:93–107PubMedCrossRefGoogle Scholar
  36. 36.
    Dirks A, Leeuwenburgh C (2002) Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 282:R519–R527PubMedGoogle Scholar
  37. 37.
    Moritani T, deVries HA (1980) Potential for gross muscle hypertrophy in older men. J Gerontol 35:672–682PubMedGoogle Scholar
  38. 38.
    Ivey FM, Roth SM, Ferrell RE et al (2000) Effects of age, gender, and myostatin genotype on the hypertrophic response to heavy resistance strength training. J Gerontol A Biol Sci Med Sci 55:M641–M648PubMedGoogle Scholar
  39. 39.
    Flynn MG, Fahlman M, Braun WA et al (1999) Effects of resistance training on selected indexes of immune function in elderly women. J Appl Physiol 86:1905–1913PubMedGoogle Scholar
  40. 40.
    Frontera WR, Meredith CN, O’Reilly KP et al (1988) Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol 64:1038–1044PubMedGoogle Scholar
  41. 41.
    Harridge SD, Kryger A, Stensgaard A (1999) Knee extensor strength, activation, and size in very elderly people following strength training. Muscle Nerve 22:831–839PubMedCrossRefGoogle Scholar
  42. 42.
    Trappe S, Williamson D, Godard M et al (2000) Effect of resistance training on single muscle fiber contractile function in older men. J Appl Physiol 89:143–152PubMedGoogle Scholar
  43. 43.
    Lambert CP, Evans WJ (2002) Effects of aging and resistance exercise on determinants of muscle strength. Journal of the American Aging Association 25:73–78Google Scholar
  44. 44.
    Sale DG (1988) Neural adaptation to resistance training. Med Sci Sports Exerc 20:S135–S145PubMedCrossRefGoogle Scholar
  45. 45.
    Trappe S, Williamson D, Godard M (2002) Maintenance of whole muscle strength and size following resistance training in older men. J Gerontol A Biol Sci Med Sci 57:B138–B143PubMedGoogle Scholar
  46. 46.
    Harman SM, Metter EJ, Tobin JD et al (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731PubMedCrossRefGoogle Scholar
  47. 47.
    Morley JE, Perry HM,3rd, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152PubMedGoogle Scholar
  48. 48.
    Sih R, Morley JE, Kaiser FE et al (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667PubMedCrossRefGoogle Scholar
  49. 49.
    Bhasin S, Storer TW, Berman N et al (1997) Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407–413PubMedCrossRefGoogle Scholar
  50. 50.
    Brodsky IG, Balagopal P, Nair KS (1996) Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3469–3475PubMedCrossRefGoogle Scholar
  51. 51.
    Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092–1098PubMedCrossRefGoogle Scholar
  52. 52.
    Urban RJ, Bodenburg YH, Gilkison C et al (1995) Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820–E826PubMedGoogle Scholar
  53. 53.
    Snyder PJ, Peachey H, Hannoush P et al (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84:2647–2653PubMedCrossRefGoogle Scholar
  54. 54.
    Welle S, Jozefowicz R, Statt M (1990) Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 71:1259–1264PubMedGoogle Scholar
  55. 55.
    Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367PubMedCrossRefGoogle Scholar
  56. 56.
    Morales AJ, Haubrich RH, Hwang JY et al (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 49:421–432CrossRefGoogle Scholar
  57. 57.
    Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL et al (1999) Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 84:1527–1533PubMedCrossRefGoogle Scholar
  58. 58.
    Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM (1995) Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 268:E268–E276PubMedGoogle Scholar
  59. 59.
    Hennessey JV, Chromiak JA, DellaVentura S et al (2001) Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 49:852–858PubMedCrossRefGoogle Scholar
  60. 60.
    Lange KH, Andersen JL, Beyer N et al (2002) GH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab 87:513–523PubMedCrossRefGoogle Scholar
  61. 61.
    Thompson JL, Butterfield GE, Marcus R et al (1995) The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 80:1845–1852PubMedCrossRefGoogle Scholar
  62. 62.
    Sullivan DH, Carter WJ, Warr WR, Williams LH (1998) Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. J Gerontol A Biol Sci Med Sci 53:M183–M187PubMedGoogle Scholar
  63. 63.
    Brill KT, Weltman AL, Gentili A et al (2002) Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 87:5649–5657PubMedCrossRefGoogle Scholar
  64. 64.
    Blackman MR, Sorkin JD, Munzer T et al (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282–2292PubMedCrossRefGoogle Scholar
  65. 65.
    Svensson J, Stibrant Sunnerhagen K, Johannsson G (2003) Five years of growth hormone replacement therapy in adults: ageand gender-related changes 11.2 Treatment of Sarcopenia and Cachexia in the Elderly in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 88:2061–2069PubMedCrossRefGoogle Scholar
  66. 66.
    Anker SD, Sharma R (2002) The syndrome of cardiac cachexia. Int J Cardiol 85:51–66PubMedCrossRefGoogle Scholar
  67. 67.
    Aquilani R, Opasich C, Verri M et al (2003) Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 42:1218–1223PubMedCrossRefGoogle Scholar
  68. 68.
    Di Francia M, Barbier D, Mege JL, Orehek J (1994) Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150:1453–1455PubMedGoogle Scholar
  69. 69.
    Schols AM, Buurman WA, Staal van den Brekel AJ et al (1996) Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51:819–824PubMedGoogle Scholar
  70. 70.
    Creutzberg EC, Casaburi R (2003) Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl 46:76s–80sPubMedCrossRefGoogle Scholar
  71. 71.
    Chai J, Wu Y, Sheng ZZ (2003) Role of ubiquitin-proteasome pathway in skeletal muscle wasting in rats with endotoxemia. Crit Care Med 31:1802–1807PubMedCrossRefGoogle Scholar
  72. 72.
    Llovera M, Carbo N, Lopez-Soriano J et al (1998) Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133:83–87PubMedCrossRefGoogle Scholar
  73. 73.
    Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269–272PubMedCrossRefGoogle Scholar
  74. 74.
    Debigare R, Cote CH, Maltais F (2001) Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 164:1712–1717PubMedGoogle Scholar
  75. 75.
    Agusti AG, Sauleda J, Miralles C et al (2002) Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:485–489PubMedCrossRefGoogle Scholar
  76. 76.
    Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871PubMedCrossRefGoogle Scholar
  77. 77.
    Libera LD, Zennaro R, Sandri M et al (1999) Apoptosis and atrophy in rat slow skeletal muscles in chronic heart failure. Am J Physiol 277:C982–C986PubMedGoogle Scholar
  78. 78.
    Smith HJ, Tisdale MJ (2003) Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis 8:161–169PubMedCrossRefGoogle Scholar
  79. 79.
    Gielen S, Adams V, Mobius-Winkler S et al (2003) Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 42:861–868PubMedCrossRefGoogle Scholar
  80. 80.
    Pu CT, Johnson MT, Forman DE et al (2001) Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 90: 2341–2350PubMedGoogle Scholar
  81. 81.
    Anker SD, Negassa A, Coats AJ et al (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361:1077–1083PubMedCrossRefGoogle Scholar
  82. 82.
    Adigun AQ, Ajayi AA (2001) The effects of enalaprildigoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail 3:359–363PubMedCrossRefGoogle Scholar
  83. 83.
    Yeh SS, Hafner A, Schuster MW et al (2003) Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 51:890–891PubMedCrossRefGoogle Scholar
  84. 84.
    Ferreira IM, Verreschi IT, Nery LE et al (1998) The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 114:19–28PubMedGoogle Scholar
  85. 85.
    Creutzberg EC, Wouters EF, Mostert R et al (2003) A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 124:1733–1742PubMedCrossRefGoogle Scholar
  86. 86.
    Saudny-Unterberger H, Martin JG, Gray-Donald K (1997) Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156:794–799PubMedGoogle Scholar
  87. 87.
    Creutzberg EC, Schols AM, Weling-Scheepers CA et al (2000) Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:745–752PubMedGoogle Scholar
  88. 88.
    Creutzberg EC, Wouters EF, Mostert R et al (2003) Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 19:120–127PubMedCrossRefGoogle Scholar
  89. 89.
    Steiner MC, Barton RL, Singh SJ, Morgan MD (2003) Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 58:745–751PubMedCrossRefGoogle Scholar
  90. 90.
    Weisberg J, Wanger J, Olson J et al (2002) Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 121:1070–1078PubMedCrossRefGoogle Scholar
  91. 91.
    Schols AM, Soeters PB, Mostert R et al (1995) Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152:1268–1274PubMedGoogle Scholar
  92. 92.
    Barber MD, Ross JA, Voss AC et al (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86PubMedCrossRefGoogle Scholar
  93. 93.
    Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. 52:1479–1486Google Scholar
  94. 94.
    Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001) Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61:3604–3609PubMedGoogle Scholar
  95. 95.
    Wigmore SJ, Ross JA, Falconer JS et al (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12:S27–S30PubMedGoogle Scholar
  96. 96.
    Calabrese L, Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108:487–495PubMedCrossRefGoogle Scholar
  97. 97.
    Haslett P, Hempstead M, Scidman C et al (1997) The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 13:1047–1054PubMedGoogle Scholar
  98. 98.
    Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V et al (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10:1501–1507PubMedCrossRefGoogle Scholar
  99. 99.
    Gullestad L, Semb AG, Holt E et al (2002) Effect of thalidomide in patients with chronic heart failure. Am Heart J 144:847–850PubMedCrossRefGoogle Scholar
  100. 100.
    Bathon JM, Genovese MC (2003) The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 21:S195–S197PubMedGoogle Scholar
  101. 101.
    Anker SD, Coats AJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123–130PubMedCrossRefGoogle Scholar
  102. 102.
    Frampton JE, Brogden RN (1995) Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 7:480–503PubMedGoogle Scholar
  103. 103.
    Doherty GM, Jensen JC, Alexander HR et al (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192–198PubMedGoogle Scholar
  104. 104.
    Biolo G, Ciocchi B, Bosutti A et al (2002) Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis 40:1162–1172PubMedCrossRefGoogle Scholar
  105. 105.
    Casey A, Constantin-Teodosiu D, Howell S et al (1996) Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol 271:E31–E37PubMedGoogle Scholar
  106. 106.
    Greenhaff PL, Bodin K, Soderlund K, Hultman E (1994) Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol 266:E725–E730PubMedGoogle Scholar
  107. 107.
    Volek JS, Duncan ND, Mazzetti SA et al (1999) Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Med Sci Sports Exerc31:1147–1156PubMedCrossRefGoogle Scholar
  108. 108.
    Bermon S, Venembre P, Sachet C et al (1998) Effects of creatine monohydrate ingestion in sedentary and weight-trained older adults. Acta Physiol Scand 164:147–155PubMedCrossRefGoogle Scholar
  109. 109.
    Brose A, Parise G, Tarnopolsky MA (2003) Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J Gerontol A Biol Sci Med Sci 58:11–19PubMedGoogle Scholar
  110. 110.
    Chrusch MJ, Chilibeck PD, Chad KE et al (2001) Creatine supplementation combined with resistance training in older men. Med Sci Sports Exerc 33:2111–2117PubMedCrossRefGoogle Scholar
  111. 111.
    Andrews R, Greenhaff P, Curtis S et al (1998) The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 19:617–622Google Scholar
  112. 112.
    Reid MB, Stokic DS, Koch SM et al (1994) Nacetylcysteine inhibits muscle fatigue in humans. J Clin Invest 94:2468–2474PubMedCrossRefGoogle Scholar
  113. 113.
    Medved I, Brown MJ, Bjorksten AR et al (2003) Nacetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J Appl Physiol 94:1572–1582PubMedGoogle Scholar
  114. 114.
    Medved I, Brown MJ, Bjorksten AR, McKenna MJ (2004) Effects of intravenous N-acetylcysteine infusion on time to fatigue and potassium regulation during prolonged cycling exercise. J Appl Physiol 96:211–217PubMedCrossRefGoogle Scholar
  115. 115.
    Hauer K, Hildebrandt W, Sehl Y et al (2003) Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med 81:118–125PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Charles P. Lambert
    • 1
  • William J. Evans
    • 1
  • Dennis H. Sullivan
    • 2
  1. 1.Department of GeriatricsNutrition, Metabolism and Exercise Laboratory, University of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Department of GeriatricsNutrition, Metabolism and Exercise Laboratory, University of Arkansas for Medical Sciences and Geriatric Research Education and Clinical Center, Central Arkansas Veterans Healthcare SystemLittle RockUSA

Personalised recommendations